Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
8
×
Tags
biotech
8
×
editas medicine
8
×
life sciences
national blog main
boston blog main
crispr
boston top stories
national top stories
san francisco blog main
boston
cancer
clinical trials
deals
gene editing
national
new york blog main
san francisco top stories
allergan
boulder/denver blog main
boulder/denver top stories
crispr therapeutics
detroit blog main
detroit top stories
fda
ipo
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
bristol-myers squibb
broad institute
What
crispr
editas
gene
medicine
bio
ceo
editing
roundup
car
cas
experimental
katrine
medicines
therapeutics
therapy
abbvie
access
acquisitions
advanced
allergan
alliance
announced
bails
beam
benefiting
big
biotech
blessing
bosley
bosley's
bosley’s
boston
brand
bridge
bridgebio
bucks
capacity
capital
cell
check
Language
unset
Current search:
photo
×
" editas medicine "
×
biotech
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M